Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We caught up with Susan Solomon, Co-Founder of The New York Stem Cell Foundation, to discuss the role of the Foundation in facilitating some of the top advances in stem cell science in recent years. Susan L Solomon is Chief Executive Officer and Co-Founder of The New York Stem Cell Foundation (NYSCF), a nonprofit organization established in 2005 to accelerate cures through stem cell research. A longtime healthcare advocate, Susan is a founding member and current President of New Yorkers for the Advancement of Medical Research, is on the Executive Committee for the
Alliance
for Regenerative Medicine, and she has been a member of the Board of Directors of the
Juvenile Diabetes
Research Foundation, New York Chapter. Susan was also a member of the Strategic Planning Committee of the Empire State Stem Cell Board. In March 2008, Susan received a New York State Women of Excellence Award from the Governor of New York. In September 2008, she received the Triumph Award from the Brooke Ellison Foundation for her work in establishing NYSCF. Prior to founding NYSCF, Susan, an attorney, spent much of her career building businesses. She established and ran Solomon Partners LLC to provide strategic management consulting to corporations, cultural institutions, foundations and nonprofit organizations. She has also held executive positions at MacAndrews and Forbes Holdings and MMG Patricof and Co. She was the founding Chief Executive Officer of Sothebys.com and was President of Sony Worldwide Networks.
...
PMID:The New York Stem Cell Foundation. Interview with Susan Solomon. 2321 Aug 23
Our team examined the characteristics of patient engagement (PE) practices in exercise-based randomized trials in
type 1 diabetes
(T1D), and facilitated T1D stakeholders in determining the top 10 list of priorities for exercise research. Two methodological approaches were employed: a scoping review and a modified James Lind
Alliance
priority-setting partnership. Published (Medline, Embase, CINAHL and Central databases) and grey literature (www.clinicaltrials.gov) were searched to identify randomized controlled trials of exercise interventions lasting minimum 4 weeks and available in English. We extracted information on PE and patient-reported outcomes (PROs) to identify if patient perspectives had been implemented. Based on results, we set out to determine exercise research priorities as a first step towards a patient-engaged research agenda. An online survey was distributed across Canada to collect research questions from patients, caregivers and healthcare providers. We qualitatively analyzed submitted questions and compiled a long list that a 12-person stakeholder steering committee used to identify the top 10 priority research questions. Of 9962 identified sources, 19 published trials and 4 trial registrations fulfilled inclusion criteria. No evidence of PE existed in any included study. Most commonly measured PROs were frequency of hypoglycemia (n=7) and quality of life (n=4). The priority-setting survey yielded 194 submitted research questions. Steering committee rankings identified 10 priorities focused on lifestyle factors and exercise modifications to maintain short-term glycemic control. Recent exercise-based randomized trials in T1D have not included PE and PROs. Patient priorities for exercise research have yet to be addressed with adequately designed clinical trials.
...
PMID:Filling gaps in type 1 diabetes and exercise research: a scoping review and priority-setting project. 3213 1